期刊文献+

安罗替尼治疗KRAS突变型晚期肺腺癌1例 被引量:44

A Case Report of Advanced Lung Adenocarcinoma Harboring KRAS Mutation Treated with Anlotinib
下载PDF
导出
摘要 近年来,晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)患者逐渐增多,治疗方法也明显增多,然而,目前对于靶向治疗表皮生长因子受体(epidermal growth factor receptor,EGFR)/间变性淋巴瘤激酶(anaplastic lymphoma kinase,ALK)耐药或化疗失败的三线及以上患者,国内外并没有标准的治疗方案,临床治疗效果也不尽如人意,安罗替尼是一种新型小分子多靶点酪氨酸激酶抑制剂,可强效抑制血管内皮细胞生长因子受体(vascular endothelial growth factor receptor,VEGFR)、血小板衍生生长因子受体(platelet-derived growth factor receptor,PDGFR)、纤维母细胞生长因子受体(fibroblast growth factor receptor,FGFR)和c-Kit等多个靶点,ALTER0303是一项关于安罗替尼作为晚期NSCLC三线治疗方案的临床研究,结果显示安罗替尼能显著延长晚期NSCLC患者的总生存期(overall survival,OS)和无进展生存期(progression-free survival,PFS),本文报道安罗替尼治疗KRAS突变型晚期肺腺癌1例。 In recent years, the number of advanced non-small cell lung cancer(NSCLC) patients has gradually increased, and the treatment methods have also been significantly increased. However, there are no standard treatment plans at home and abroad for third-line and above patients who are refractory to targeted therapy epidermal growth factor receptor(EGFR)/anaplastic lymphoma kinase(ALK) or chemotherapy. The clinical treatment effect is also not satisfactory. Anlotinib is a novel TKI targeting the vascular endothelial growth factor receptor(VEGFR), fibroblast growth factor receptor(FGFR), platelet-derived growth factor receptor(PDGFR) and c-Kit. ALTER0303 trail, phase Ⅲ study has demonstrated that Anlotinib significantly prolonged overall survival(OS) and progression-free survival(PFS) in advanced NSCLC patients as 3 rd line treatment.Here we report a case of advanced lung adenocarcinoma harboring KRAS mutation treated with Anlotinib.
作者 苏雨栋 孟昭婷 徐晓燕 王心悦 左冉 侯云霞 李凯 陈鹏 Yudong SU;Zhaoting MENG;Xiaoyan XU;XinYue WANG;Ran ZUO;Yunxia HOU;Kai LI;Peng CHEN(Department of Thoracic Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin Clinical Research Center for Cancer, Tianjin 300060, Chin)
出处 《中国肺癌杂志》 CAS CSCD 北大核心 2018年第5期428-430,共3页 Chinese Journal of Lung Cancer
基金 天津市科委面上项目(No.13JCYBJC23600) 天津市卫生局科技基金(No.2015KZ085)资助
关键词 安罗替尼(Anlotinib) 肺肿瘤 晚期肺癌 Anlotinib Lung neoplasms Advanced lung cancer
  • 相关文献

同被引文献327

引证文献44

二级引证文献285

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部